Aberrantly enhanced vascular endothelial growth factor (VEGF) gene expression is associated with increased tumor growth and metastatic spread of solid malignancies, including human renal carcinomas. Persistent activation of STAT3 is linked to tumor-associated angiogenesis, but underlying mechanisms remain unclear. Therefore, we examined whether STAT3 modulates the stability and activity of hypoxia-inducible factor-1α (HIF-1α), and in turn enhances VEGF expression. We found that STAT3 was activated in ischemic rat kidneys and hypoxic human renal carcinoma cells. We also found that hypoxia-induced activation of STAT3 transactivated the VEGF promoter and increased the expression of VEGF transcripts. Consistent with these findings, STAT3 inhibition attenuated the hypoxic induction of VEGF. Interestingly, activated STAT3 increased HIF-1α protein levels due to the HIF-1α stability by blocking HIF-1α degradation and accelerated its de novo synthesis. The novel interaction of STAT3 with HIF-1α was identified in hypoxic renal carcinoma cells. Furthermore, hypoxia recruited STAT3, HIF-1α, and p300 to the VEGF promoter and induced histone H3 acetylation. Therefore, these findings provide compelling evidence that a causal relationship exists between STAT3 activation and HIF-1-dependent angiogenesis and suggest that therapeutic modalities designed to disrupt STAT3 signaling hold considerable promise for the blocking tumor growth and enhancing apoptosis of cancer cells and tissues. ignal transducers and activators of transcription (STAT) comprises a family of cytoplasmic transcription factors that transmit signals, usually generated at cell surface receptors, to the nucleus, where STATs bind to specific DNA promoter sequences and thereby regulate gene expression (1). The resulting signal transduction pathways permit them to play different roles in normal physiological cell processes, such as differentiation, proliferation, apoptosis, and angiogenesis (2). However, compared with normal cells and tissues, constitutively activated STATs have been detected in a wide variety of human cancer cell lines and primary tumors, such as blood malignancies (leukemia, lymphoma, multiple myeloma) and solid neoplasias (head and neck, brain, breast, lung, pancreas, prostate cancers) (3-9). Many studies suggested that STAT proteins could participate in tumorigenesis through up-regulation of genes encoding apoptosis inhibitors (Mcl-1, Bcl-xL), cell-cycle regulators (cyclin D1/D2, c-Myc), and inducers of angiogenesis (VEGF) (10). STAT3 is also involved in tumor progression through inducing angiogenic factors, such as VEGF (11). These findings together underscore the ability of aberrant STAT3 activation to induce permanent changes in gene expression programs that ultimately lead to the malignant phenotype.
ignal transducers and activators of transcription (STAT) comprises a family of cytoplasmic transcription factors that transmit signals, usually generated at cell surface receptors, to the nucleus, where STATs bind to specific DNA promoter sequences and thereby regulate gene expression (1) . The resulting signal transduction pathways permit them to play different roles in normal physiological cell processes, such as differentiation, proliferation, apoptosis, and angiogenesis (2) . However, compared with normal cells and tissues, constitutively activated STATs have been detected in a wide variety of human cancer cell lines and primary tumors, such as blood malignancies (leukemia, lymphoma, multiple myeloma) and solid neoplasias (head and neck, brain, breast, lung, pancreas, prostate cancers) (3) (4) (5) (6) (7) (8) (9) . Many studies suggested that STAT proteins could participate in tumorigenesis through up-regulation of genes encoding apoptosis inhibitors (Mcl-1, Bcl-xL), cell-cycle regulators (cyclin D1/D2, c-Myc), and inducers of angiogenesis (VEGF) (10) . STAT3 is also involved in tumor progression through inducing angiogenic factors, such as VEGF (11) . These findings together underscore the ability of aberrant STAT3 activation to induce permanent changes in gene expression programs that ultimately lead to the malignant phenotype.
Reduction in tissue oxygen tension (hypoxia) is an important stimulus to change many physiological and pathological processes (12) . Under hypoxic conditions, the diverse genes are transcriptionally up-regulated by a heterodimeric transcription factor, HIF-1. Its activation is highly associated with cancer cell growth and survival, tumor development, and angiogenesis. The α subunit of HIF-1 is the hypoxia-responsive component, while the β subunit is expressed constitutively. Under normoxic conditions, HIF-1α is rapidly degraded by the ubiquitinproteasome pathway (13) . Ubiquitination of HIF-1α is mediated by interaction with pVHL (von Hippel-Lindau tumor suppressor protein) (14) and p53. The oxygen-dependent degradation domain (ODDD) is modified under normoxic conditions and in turn targeted by VHL-E3 ligase complex, resulting in its proteasomal degradation. Under hypoxic conditions, HIF-1α is stabilized due to the inhibition of HIF-1α-modifying enzymes, such as prolyl hydroxylases and ARD1 acetyl transferase (15) . Stabilized HIF-1α exerts transcriptional activity using its transactivation domains, which recruit p300/CBP coactivators (16, 17) , SRC-1 (steroid receptor coactivator-1) family coactivators, or nuclear redox regulator . Hypoxia is a common feature found in solid tumors, and closely related with malignant progression, resistance to radiotherapy and chemotherapy, and increased metastasis (19) . Aberrant activation of STAT3 is also commonly observed in tumors and strongly associated with tumor development and progression. Taken together, it is possible that tumor hypoxia and STAT3 activation synergistically aggravate tumor progression when two events concomitantly occur in tumors. Thus, it is worthwhile to investigate the relationship between HIF-1 and STAT3 in tumor progression for understanding tumor pathogenesis and for finding the target for anticancer therapy.
In the present study, we found that STAT3 was activated in hypoxia-stimulated human renal carcinoma cells. We also found that the transcriptional activation of the VEGF promoter was mediated by active STAT3. Furthermore, active STAT3 interacted with HIF-1α and increased HIF-1α accumulation in the hypoxic cells. Taken together, our findings provide the first evidence that hypoxia-activated STAT3 plays a pivotal role in regulation of HIF-1α protein stability and enhances HIF-1-mediated expression of VEGF through interacting with HIF-1α in cancer cells.
MATERIALS AND METHODS

Materials
AG490, cycloheximide, MG132, CoCl 2 , desferrioxamine (DFO) were obtained from SigmaAldrich Corp (St. Louis, MO). The anti-phospho-specific antibodies that recognize a phosphoactivated form of STAT3 and anti-STAT3, anti-GFP were purchased from Santa Cruz Biotechnology. HIF-1α antibodies were generated from rabbits by using bacterially expressed ODDD peptides, as reported previously (20) Cell culture and hypoxia Caki I (renal carcinoma, ATCC, Manassas, VA), COS7 (African green monkey kidney cell, ATCC) were maintained in DMEM medium supplemented with 10% heat-inactivated fetal bovine serum and antibiotics at 37°C with 95% air and 5% CO 2 . For hypoxic conditions, the cells were placed in airtight chamber, which was flushed with 1% O 2 , 5% CO 2 , and 94% N 2 at 37°C, and incubated for the indicated time. In additional experiments, cells were incubated in containing 100 µM CoCl 2 under normoxic conditions.
Preparation of ischemic renal tissue
Sprague-Dawley rats weighing ~300 g were anaesthetized with ketamine/xylazine. A small vascular clamp was used to occlude the renal artery for 2 h, 4 h while the animal was kept at 37°C with heating blanket. All animal procedures were performed according to the procedures in the Seoul National University Laboratory Animal Maintenance Manual. After isolation of kidney, the tissue was homogenized in 25 mM HEPES (pH 7.5), 0.1% Triton X-100, 5 mM MgCl 2 , 2 mM DTT, 74 µM antipain, 0.15 µM aprotin, 1.3 mM EDTA, 1 mM EGTA, 15 µM pepstain, and 20 µM leupeptin.
Transient transfection and luciferase assay
Cells were seeded onto 24-well plates at a density 4 × 10 4 cells/well and incubated for 24 h in media. The plasmids were transfected into cells using LipofectAMINE method (Invitrogen, San Diego, CA) according to the manufacturer's instruction. Cells were cotransfected with various combinations the following constructs; wild-STAT3. mutant-STAT3YF (250 ng of plasmid each) in association with m67 luciferase reporter construct (all gifts from M. Shong, Laboratory of Endocrine Cell Biology, Chungnam National University School of Medicine, Daejeon, Korea); the VEGF reporter construct containing -2.7 kb of the VEGF promoter region. After transfection, the cells were lysed and luciferase assay was performed using a luciferase assay kit (Promega Corp., Madison, WI). The transfection efficiency was normalized by the value of cotransfected Renilla luciferase.
Immunofluorescence analysis
Cells (10 µl) were plated onto slides at a density 1 × 10 6 cells/ml. The cells onto slides were fixed with 4% paraformaldehyde for 5 min at RT. After washing, cells were permeabilized with 0.1% Trioton X-100 in PBS for 20 min on ice. Cells were blocked with 3% BSA solution in PBS and 10% goat sera for 1 h at 37 degree and then incubated 1 h at 37 degree with anti-STAT3 (Santa Cruz Biotechnology Inc., Santa Cruze, CA) diluted 1: 150 in blocking solution. Donkey anti-mouse sera (The Jacksons Laboratory) was used as a secondary antibody (1:300 dilution in blocking solution, 1 h incubation). After mounting, cells were observed in 400×.
Western blot analysis
Total cell lysate was separated on 8% SDS/polyacrylamide gel and transferred onto Hybond enhanced luminescence membranes (Amersham Pharmacia Biotech, Arlington Heights, IL). Membrane were blocked with 5% nonfat milk in Tris-buffered saline containing 0.1% Tween20 (TTBS) at room temperature for 1 h and then incubated overnight at 4°C with anti-GFP, antiphospho-STAT3, anti-STAT3, anti-HIF1α (Santa Cruz Biotechnology) diluted 1:1000 in 5% nonfat milk in TTBS. Horseradish peroxidase-conjugated antimouse or antirabbit serum (Santa Cruz Biotechnology) was used as a secondary antibody (1:5000 dilution in 5% nonfat milk in TTBS, 1 h incubation) and the antigen antibody complexes were visualized using an Enhanced Chemiluminescence Plus kit (Amersham Biosciences Corp., Piscataway, NJ).
RNA isolation and RT-PCR
Total RNA was extracted with Trizol reagent (Invitrogen). RNA was quantified by measuring absorbance at 260 nm, and the ratio of absorbance at 260 nm to that at 280 nm was 1.8 or higher. Finally, the integrity of RNA was checked by visual inspection of the two rRNAs 28S and 18S on an agrose gel. cDNA was prepared by incubating 1 µg of total RNA in 50 mM Tris-HCl, pH 8.3; 75 mM KCl; 3 mM MgCl 2 ; 10 mM dithithreitol; and RNase inhibitors with 250 units of avian myeloblastosis virus-reverse transcriptase (Promega), 1 µΜ of each dNTP, and random primer (0.05 µΜ) for 60 min at 37°C. The cDNA fragment was amplified by PCR using following specific primers; VEGF, sense 5′-AGGAGGGCAGAATCATCACG-3′, and antisense 5′-CAAGGCCCACAGGGATTTTCT-3′. PCR was initiated in a thermal cycle programmed at 95°C for 5 min, 94°C for 1 min, 58°C for 1 min, and 72°C for 1 min and amplified for 25 cycles. The amplified products were visualized on 1% agarose gel.
ELISA
VEGF production in culture supernatants was examined using a human VEGF-specific ELISA (Quantikine; R&D Systems, Minneapolis, MN) normalized to total protein content as measured by Bradford assay.
Coimmunoprecipitation
After COS7 cells were stabilized for 24 h after transfection, the cells were incubated for 6 h under hypoxic or normoxic conditions before harvesting cells. Cells were lysed on ice in 25 mM HEPES (pH 7.7), 0.4 M NaCl, 1.5 mM MgCl 2 , 2 mM EDTA, 1% Triton X-100, 0.5 mM DTT, and protease inhibitor mixture (Roche). Complexes were immunoprecipitated by anti-phospho-STAT3 (Y705) antibody/protein G-Sepharose (Pierce) at 4°C for 2 h. Bindings and washes were performed in the same buffer, except the NaCl concentration was diluted fourfold. Coimmunoprecipitated HIF-1α protein was detected by immunoblotting using the HIF-1α -specific antibody.
Electrophoretic mobility shift assay
The STAT3-DNA complex and free DNA were separated using PAGE and visualized by autoradiography. The putative STAT3 binding site (5′-ATCCCTGGACACTTCCCAAAGGAC-3′) of the human VEGF promoter was used to design the probe (11) . This oligonucleotide was hybridized with its complementary oligonucleotide (5′-GTCCTTTGGGAAGTGTCCAGGGAT-3′) at 45-55°C for 10 min using annealing buffer. The double-stranded DNA probe was endlabeled using T4 polynucleotide kinases and [γ-32P] ATP and used in all EMSA. Radiolabeled oligonucleotides were incubated for 20 min at room temperature in a total volume of 20 µl containing 2.5-5.0 µg of nuclear protein, and radiolabeled oligonucleotide. Electrophoresis through a 6% polyacrylamide gel was carried out in 0.5× TBE buffer for 1.2 h at 300V. The gel was then dried and exposed to X-ray film. STAT3 proteins bound to the VEGF promoter were identified by supershift with antibodies specific for STAT3 (Santa Cruz Biotechnology). Nuclear proteins were incubated with 1 µg/µl of the anti-STAT3 polyclonal antibody for 20min on ice before the addition of radiolabeled oligonucleotide.
Chromatin immunoprecipitation assay
Chromatin Immunoprecipitation were based on protocol described previously (21) . Cells were fixed by formaldehyde. Soluble chromatin samples were immunoprecipitated with anti-STAT3, anti-HIF1α, anti-p300, anti-acetylated H3 antibody at 4°C overnight. DNA isolated from immunoprecipitated material following reversal of formaldehyde crosslinking was amplified by PCR. Promoter-specific primers included human VEGF, 5′-AGACTCCACAGTGCATACGTG-3′ and 5′-AGTGTGTCCCTCTGACAATG-3′, which amplify 235bp fragments flanking the STAT3 binding element, HIF-1 binding element.
RESULTS
STAT3 is activated in hypoxic human renal carcinoma cells and ischemic rat kidney
To investigate the activation of STAT3 by hypoxia, we examined the nuclear localization state of active STAT3 with an anti-STAT3 antibody using immunoflorescence analysis (Fig. 1A) . STAT3 was localized in the cytoplasm rater than the nucleus under normoxic conditions in Caki I cells. By contrast, we could detect the active forms of STAT3 in the nucleus under hypoxic conditions. We next determined whether hypoxia stimulations were able to activate STAT3 protein. To do this, Caki I cells were exposed hypoxia for 6 h and analyzed the phosphorylation state in tyrosine-705 of STAT3 with a phosphotyrosine-specific antibody (anti-phospho-STAT3) by immunobloting (Fig. 1B) . We found the tyrosine 705 phosphorylation of STAT3 in hypoxiastimulated Caki I cells. In addition, we obtained similar findings in rat kidneys, which had been subjected to ischemia for 2, 4 h (Fig. 1C) . Y705 phosphorylation of STAT3 is known to be important for the dimerization, translocation, and transcriptional activation of STAT3. Likewise, we also found the tyrosine 701 phosphorylation of STAT1 in hypoxia-stimulated in Caki I cells (data not shown). In immunohistochemical analysis, active forms of STAT3 were detected in dysplastic region of the human renal carcinoma, in addition HIF-1α was also detected in such regions (data not shown). Therefore, we speculated that an oncogenic target gene could be induced by the phosphorylation of STAT3 in hypoxic-stimulated tumor cells.
To examine the relationship between VEGF secretion and phosphorylation of STAT3 under hypoxic conditions, we evaluated secreted protein level of VEGF. We found no secretion of VEGF within 6 h under hypoxic conditions (Fig. 1D ). This result indicates that phosphorylation of STAT3 by hypoxia was not related to downstream pathway of VEGF/VEGFR interaction.
Hypoxic activation of STAT3 enhances the transcription of the VEGF gene
To determine the role of STAT3 in adaptive processes to hypoxia, we first examined the transcriptional activation of VEGF gene, whose expression is directly regulated by HIF-1 and plays a key role in hypoxic adaptation. We performed a promoter assay using a VEGF promoter reporter plasmid m67, which was inserted with ~2.7 kb of the 5′-flanking region of the human VEGF gene. We transfected the reporter plasmid into Caki I cells. Hypoxia induced luciferase activity (~8-fold) relative to normoxia (Fig. 2A, first two columns) and it was further increased (~3-fold) by cotransfection with wild type of STAT3 compared with mock transfection under hypoxia ( Fig. 2A, second, fourth columns) . To examine whether the hypoxic activation of the reporter is mediated by STAT3 activated by hypoxia, we co-transfected cells with the plasmid RcCMV-STAT3YF encoding the dominant-negative form of STAT3, and found that STAT3YF diminished the hypoxia-mediated reporter activation. The involvement of STAT3 in the hypoxic activation of the VEGF promoter was confirmed using an AG490, JAK2 inhibitor well known to inhibit JAK2/STAT3 pathway (22) (Fig. 2A) . These observations suggest that hypoxia increases VEGF expression via STAT3 activation in Caki I cells. The involvement of STAT3 in hypoxic activation of the VEGF promoter was re-examined using the STAT3-deficient cell line, COS7. Hypoxia induced the VEGF promoter activity (~8-fold) relative to normoxia (Fig. 2B, first two  columns) . This induction was due to HIF-1 because both HIF-1 and STAT3 have been implicated in mediating VEGF transcription (11) . As expected in STAT3-deficeint COS7 cells, STAT3YF, and AG490 did not affect the reporter activity. However, it was further increased (~2-fold) by cotransfection with wild type of STAT3 compared with mock transfection under hypoxia (Fig. 2B) . Moreover, triple transfection with STAT3, HIF-1α, and p300 remarkably increased the reporter activity under hypoxic conditions, and similar results were obtained with CBP expression plasmid instead of p300 plasmid (data not shown). These results suggest that the transcriptional coactivators can functionally cooperate with STAT3 in the hypoxic induction of VEGF transcription.
Therefore, active forms of STAT3 are likely to be involved in hypoxic induction of VEGF. Thus we checked mRNA levels of VEGF using RT-PCR. Caki I cells were pretreated with 30 µM AG490 for 1 h and exposed to hypoxia or CoCl 2 for 24 h. Both stimuli increased VEGF transcript levels, and AG490 attenuated these hypoxic inductions (Fig. 2C) . Furthermore, the mRNA expression of VEGF was increased by overexpressed STAT3 compared with hypoxia alone (data not shown). These results indicate that STAT3 activity is indispensable for hypoxiainduced VEGF expression, which is also in consistent with the above results on the VEGF promoter activity (Fig. 2A, B) .
STAT3 increases the cellular levels of HIF-1α either by blocking protein degradation or by enhancing HIF-1α synthesis under hypoxic conditions
To determine the relationship between HIF-1α and the hypoxic activated STAT3, we checked HIF-1α protein levels under STAT3-inhibited conditions. AG490 inhibited the expression of HIF-1α as well as the phosphorylation of STAT3 under hypoxic conditions (Fig. 3A) . The HIF-1α expression was also decreased in cells transfected with dominant negative mutant STAT3YF (Fig. 3B) . These data indicate that STAT3 is involved in the hypoxic expression of HIF-1α protein and lead us to suppose that STAT3 up-regulates the activity of HIF-1α, because HIF-1α activity is primarily regulated by the amount of HIF-1α protein.
To test whether STAT3 increases the stability of HIF-1α protein, we measured the half-life of HIF-1α protein after blocking de novo protein synthesis with cycloheximide. COS7 cells were transfected with wild-type STAT3 and incubated with 130 µM desferoxamine (DFO), an iron chelator, has been shown to activate HIF-1 in vitro, with kinetics similar to those associated with hypoxia (23) . After cells were treated with 60 µg/ml of cycloheximide, total proteins were extracted at the indicated times, and subjected to Western blot analysis to determine HIF-1α protein level. Figure 3C shows that the half-life of HIF-1α was prolonged to 50 min in the presence of STAT3, whereas that in the absence of STAT3 was 25 min. This result suggests that STAT3 further stabilized HIF-1α protein under hypoxic conditions. We next checked the de novo protein synthesis of HIF-1α after blocking protein degradation with MG132, a proteasome inhibitor. COS7 cells were transfected with wild-type STAT3 and treated with 20 µM MG132. Total proteins were extracted at the indicated times and subjected to Western blot analysis to determine HIF-1α protein level. Figure 3D shows that synthesis of HIF-1α in transfected cells with STAT3 were processed earlier by 2 h than transfected cells with an empty vector. Under these conditions, we checked mRNA levels of HIF-1α by RT-PCR. The HIF-1α mRNA expression in transfected cells with STAT3 were induced earlier by 2 h than transfected cells with an empty vector (data not shown).
Taken together, STAT3 seems to be a new regulator that enhances HIF-1α stability under hypoxic conditions and accelerates protein synthesis.
STAT3 interacts with HIF-1α and recruits on the human VEGF promoter in response to hypoxia
STAT3 showed an additional enhancement of the hypoxic expression of VEGF (Fig. 2B) . Thus we hypothesized that the VEGF expression is cooperatively regulated by HIF-1α and STAT3. To test this hypothesis, we first checked the interaction between HIF-1α and STAT3 using the coimmunoprecipitation assays. COS7 cells were transfected with STAT3WT plasmids and incubated under hypoxic condition. Cell lystates were immunoprecipitated with an anti-phospho-STAT3 (Y705) antibody, followed by Western blotting with an anti-HIF-1α antibody. As shown in Fig. 4A , the HIF-1α was co-precipitated with phospho-STAT3 in hypoxic cells, thus demonstrating the association between HIF-1α and phospho-STAT3 under hypoxic conditions. To confirm whether this association is specific to activated STAT3 or not, we performed coimmunoprecipitation assays using dominant negative mutant of STAT3, STAT3-Y705F expression plasmids. This mutant construct is substituted phenylalanine for tyrosine 705 residue of STAT3. We found that HIF-1α did not bind unphosphorylated STAT3 in COS7 cells transfected with STAT3YF plasmid under hypoxic conditions (Fig. 4A) . Interestingly, we found that cytokine stimulation also induced the association between STAT3 and HIF-1α. Interlukin-6 (IL-6) and leukemia inhibitory factor (LIF) known to phosphorylate STAT3 were treated to STAT3 and HIF-1α expressed COS7 cells. Phosphorylated STAT3 by IL-6 or LIF was associated with overexpressed HIF-1α under normoxic conditions (Fig. 4A ). These results demonstrate that association between STAT3 and HIF-1α is dependent on phosphorylation of STAT3.
Next, to clarify the binding site of HIF-1α for the association with STAT3, we performed coimmunoprecipitation assays using series of deletion constructs of HIF-1 α. The results shown in Fig. 4B indicated that 577-826 regions of HIF-1α were captured by the interaction with STAT3, whereas the amino acids 1-400 and including ODD domain of HIF-1α were not interacted. The coincidence of the putative STAT binding motif (5′-ATCCCTGGACACTTCCCAAAGGAC-3′) (11) in the human VEGF promoter led us to the hypothesis that STAT3 binds to this motif and induce transcription of the VEGF gene. To address this, we examined the binding of STAT3 to the putative STAT binding motif by electrophoretic mobility shift assay (EMSA). Hypoxia induced STAT3 DNA binding activity on the motif, and these STAT3-DNA complexes was supershifted with anti-STAT3 antibody (Fig. 4C) .
To test whether STAT3 in association with HIF-1α recruits to the human VEGF promoter, we performed ChIP assays on chromatin samples from normoxic and hypoxic cells. Occupancy of the promoter was analyzed using specific pairs of primers spanning both the STAT3 binding motif and HIF-1α binding motif. Significantly increased binding of STAT3 to the promoter was seen in the hypoxia (Fig. 4D) . The binding of HIF-1α and p300 to the promoter was also significantly enhanced under hypoxic conditions. In addition, we observed H3 histone acetylation by intrinsic HAT activity of transcriptional coactivator, p300 under hypoxic conditions (Fig. 4D) . Under hypoxic conditions, stabilized HIF-1α exerts its transcriptional activity by binding to p300/CBP (17) , which synergistically enhances HIF-1α-mediated transcriptional activation under hypoxic conditions. It is well known that p300 binds both STAT3 and HIF-1α. The modulation of HIF-1α stability and activation requires the interaction between HIF-1α and multiple proteins. In this respect, our data suggest that STAT3 should be considered as a new regulator of HIF-1α activity by participating in the transcriptional unit with HIF-1α and p300 (Fig. 4) , which leads to hypoxia-mediated transcriptional activation of HIF-1 target genes such as VEGF (Fig. 5) .
DISCUSSION
In the present study, we demonstrate that STAT3 is a novel and essential component of HIF-1 regulatory machinery through associating with HIF-1α under hypoxic conditions. We found the significant increase of tyrosine phosphorylation of STAT3 and nuclear localization of active form of STAT3 in Caki I, human renal carcinoma cells, under hypoxic conditions. To our best knowledge, it is the first finding that hypoxia-phosphorylated STAT3 directly binds HIF-1α and up-regulates HIF-1α stability through delaying protein degradation and accelerating protein synthesis in human renal carcinoma cells. The regulation of HIF-1α stability and activity occurs at multiple levels. The modulation of HIF-1α protein through itself and other proteins interaction is pivotal in stabilization and activation of HIF-1α protein. We identified a novel interaction between HIF-1α and STAT3 using coimmunoprecipitation assays. Especially, we found that HIF-1α did not bind unphosphorylated STAT3 in COS7 cells transfected with STAT3YF plasmid under hypoxic conditions. Also, we found that cytokine stimulation also induced the association between STAT3 and HIF-1α. Phosphorylated STAT3 by IL-6 or LIF was associated with overexpressed HIF-1α under normoxic conditions. These results demonstrate that association between STAT3 and HIF-1α is dependent on phosphorylation of STAT3.
Since hypoxia represents a characteristic of tumors, the hypoxic stress may provide a common signal that induces a prolonged increase in angiogenic gene expression during tumorigenesis. HIF-1 is known to be critical for tumor growth and progression. The elevated levels of HIF-1 and VEGF proteins are observed in a variety of primary malignant tumors (24) . The expansion of tumor mass depends strictly on the development of new blood vessels. Hypoxia is a strong stimulus for angiogenesis in cancer. Cells in tumors become hypoxic when too distant from nearby vessels and respond to hypoxia-producing angiogenic factors (25) (26) (27) (28) (29) . One of the most specific and potent angiogenic factors is vascular endothelial growth factor (VEGF). Both HIF-1 and STAT3 have been implicated in mediating VEGF transcription (11) , but the simultaneous binding of each transcription factor to the VEGF promoter by hypoxia has not been examined. The HIF-1 regulatory region of the VEGF promoter (-985 to -935bp) contains a STAT3 element 86bp downstream that has been implicated in VEGF transcription. Interestingly, we found that hypoxia-induced VEGF expression was significantly blocked by STAT3 inhibition. It is well known that HIF-1 is a transcription factor that has been shown to be essential for VEGF transcriptional activation. However, our results demonstrate that STAT3 is a new regulator of VEGF expression under hypoxic conditions and hypoxia-mediated VEGF expression requires binding of both STAT3 and HIF-1α to the VEGF promoter for maximum induction in renal carcinoma cells.
To clarify a molecular mechanism of the cooperation between STAT3 and HIF-1α on VEGF expression, we examined the recruitment of STAT3, HIF-1α, and p300 on the human VEGF promoter under hypoxic conditions. We found that STAT3, HIF-1α, and p300 all recruit on the human VEGF promoter under hypoxic conditions in human renal carcinoma cells. HIF-1α contains two transactivation domains, which confer transcriptional activation of the target genes by associating with general transcriptional factors such as CBP/p300, TIF2, or SRC-1 (30) (31) (32) (33) . It was reported that STAT3 could interact p300, thus modulating a subset of p300 activities. Also, it was reported that the recruitment of CBP/p300 is mediated by Asn-803 C-terminal transactivation domain in HIF-1α. Our results demonstrate that the amino acids 577-826 regions, C-terminal domain of HIF-1α are interacted with STAT3. The p300 may play a role of linker protein between STAT3 and HIF-1α forming multi-complex for transcriptional regulation on VEGF promoter under hypoxia. Also, we found that hypoxia induces H3 histone acetylation on the human VEGF promoter. The CBP/p300 cofactor is a histone acetyl-transferase known to be recruited by many transcription factors. Histone acetylation modulates chromatin structure to "open" the genomic locus for increased transcriptional activity (34) . In our present studies, the addition of exogenous STAT3 increase the transcriptional activity of the human VEGF promoter and co-addition of with exogenous STAT3, HIF-1α, and p300 remarkably increase the transcriptional activity under hypoxia. This may represents the full activation of VEGF promoter by transcriptional unit forming complex STAT3/ HIF-1α/ p300.
Based on these findings, blocking STAT3 is expected to inhibit the VEGF up-regulation that is induced by many oncoproteins and growth signal in solid tumor cells. Furthermore, our findings suggest a novel function of STAT3 as a new regulator of hypoxia-induced angiogenesis in human renal carcinoma. Therefore, STAT3 inhibition can be application for clinical therapy in patients with solid tumor by reducing HIF-1α protein induction and VEGF expression. 1 . STAT3 is activated in human renal carcinoma cells and ischemic rat kidney. A) Caki I cells were exposed to hypoxia (1% O 2 ) for 6 h. Cells were subjected to Immunoflorescence assay using anti-STAT3 antibody. B) Caki I cells were exposed to hypoxia (1% O 2 ) for 6 h. Total cell extracts were separated on 8% SDS-PAGE and subjected to Western blot assay using anti-phospho-STAT3 (Y705), anti-phospho-STAT3 (S727), and anti-STAT3 antibodies. C) Tissue homogenates of kidneys that were obtained from rats at ischemia for 2 and 4 h and subjected to Western blot assay assay using anti-phospho-STAT3 (Y705) and anti-STAT3 antibodies. D) Caki I cells were subjected to normoxia or hypoxia for 6, 12, and 24 h, and ELISA was used to determine VEGF concentrations of supernatant. , wild-type HIF-1α, p300 in association with m67 luciferase reporter construct; the VEGF reporter construct containing -2.7 kb of the VEGF promoter region. After 1 h pretreatment of AG490 or 24 h posttransfection, cells were exposed to hypoxia (1% O 2 ) for 24 h. Then cell lysates were subjected to the luciferase activity assay. C) Caki I cells were pretreated with 30 µM AG490 for 1 h and then exposed to hypoxia (1% O 2 ) or 100 µM CoCl 2 for 24 h. Reverse transcriptase-PCR analysis was performed using a specific primer for VEGF and beta-actin. synthesis under hypoxic conditions. A) Caki I cells were pretreated for 1 h with 30 µM AG490, then were exposed to hypoxia (1% O 2 ) for 6 h. Total cell extracts were separated on 8% SDS-PAGE and subjected to Western blot assay using anti-phospho-STAT3 (Y705), anti-STAT3, anti-HIF-1α, and anti-β-actin antibodies. B) Caki I cells were transfected with dominant-negative form of STAT3 (RcCMV-STAT3YF), and incubated for an additional 24 h. Then these cells were exposed to hypoxia (1% O 2 ) for 6 h. Total cell extracts were separated on 8% SDS-PAGE and subjected to Western blot assay using anti-phospho-STAT3 (Y705), anti-STAT3, anti-HIF-1a, and anti-ß-actin antibodies. C) COS7 cells were transfected with wild-type of STAT3, and the cells were incubated with 130 µM DFO. Then, the cells were incubated 60 µg/ml cycloheximide for indicated time. Total cellular protein extracts were subjected to Western blot analysis to determine HIF-1α protein level. D) COS7 cells were transfected with wild-type of STAT3, and the cells were incubated with 20 µM MG132 for indicated time. Total cellular protein extracts were subjected to Western analysis to determine HIF-1α protein level. The expression level of wild-type of STAT3 blot was analyzed using anti-STAT3 antibody. Fig. 4 (cont)   Figure 4 . STAT3 interacts with HIF-1α and recruits on the human VEGF promoter in response to hypoxia. A) COS7 cells were transfected with STAT3WT or STATYF or HIF-1α WT and then cells were exposed to hypoxia (1% O 2 ) for 6 h or treated with 10 nM lL-6, LIF for 15 min. Cell extracts were prepared and immunoprecipitated with a anti-phospho-STAT3 specific antibody: immunoprecipitates were developed on Western blots with a HIF-1α specific antibody. The expression level of wild-type of STAT3 was analyzed using anti-STAT3 antibody. B) COS7 cells were transfected with series of deletion constructs of GFP-HIF-1α and STAT3WT, and then cells were exposed to hypoxia (1% O 2 ) for 6 h. Cell extracts were prepared and immunoprecipitated with an anti-phospho-STAT3 specific antibody: immunoprecipitates were developed on Western blots with an anti-GFP specific antibody. The expression level of wild-type of STAT3 was analyzed using anti-STAT3 antibody. C) DNA binding activity of STAT3 in Caki I cells exposed to hypoxia (1% O 2 ) for 6 h detected by EMSA. Nuclear extracts were prepared and incubated in the absence or presence of anti-STAT3 antibody in combination with a 32 P-labeled STAT3 oligonucleotide probe corresponding to the putative binding site in human VEGF promoter. D) ChIP assay, soluble chromatin was prepared from Caki I cells exposed to hypoxia (1% O 2 ) for 6 h and immunoprecipitated anti-STAT3, anti-HIF-1α, anti-p300, and anti-H3 acetylation antibodies. The final DNA extractions were amplified using pairs of primers that cover putative STAT3 binding site of the human VEGF promoter. hypoxia. Hypoxic activated STAT3 increases HIF-1α protein stability and binds to the human VEGF promoter. STAT3 should be considered as a new regulator of HIF-1α activity by participating in the transcriptional unit with HIF-1α and p300, which leads to hypoxia-mediated transcriptional activation of HIF-1 target genes such as VEGF.
